The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines' targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy. The drug, branded as Rasonque and also known as...
Continue reading...
[ H/T Newsmax ]
